Breast cancer: Current and future endocrine therapies

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 695-723

  Palmieri, Carlo ^a,b,c   Patten, Darren K ^d   Januszewski, Adam ^d   Zucchini, Giorgia ^e   Howell, Sacha J ^e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Breast cancer; Endocrine therapy; Targeted therapy

Indexed keywords

ABIRATERONE ACETATE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AZDO 250; BOSUTINIB; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DASATANIB; DIETHYLSTILBESTROL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTRADIOL; EVEROLIMUS; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR; FULVESTRANT; GONADORELIN DERIVATIVE; HISTONE DEACETYLASE; INSULIN RECEPTOR; IROSUSTAT; LETROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PREDNISOLONE; PROTEIN KINASE B; SARACATINIB; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANOREXIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DIZZINESS; DRUG TARGETING; DYSPNEA; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FLUSHING; HEART PALPITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; LOW DRUG DOSE; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); METASTASIS; NAUSEA; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

BREAST CANCER; ENDOCRINE THERAPY; TARGETED THERAPY;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; ESTROGENS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN;

EID: 84888327047     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.08.001     Document Type: Review

References (275)

1. Aebi S., Davidson T., Gruber G., Cardoso F., ESMO Guidelines Working Group Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011, 22(Suppl 6):vi12-vi24.
2. Afhüppe W., Beekman J.M., Otto C., Korr D., Hoffmann J., Fuhrmann U., Möller C. In vitro characterization of ZK 230211-a type III progesterone receptor antagonist with enhanced antiproliferative properties. J. Steroid Biochem. Mol. Biol. 2010, 119:45-55.
3. Alba E., Calvo L., Albanell J., De la Haba J.R., Arcusa Lanza A., Chacon J.I., Sanchez-Rovira P., Plazaola A., Lopez Garcia-Asenjo J.A., Bermejo B., Carrasco E., Lluch A., GEICAM Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012, 23:3069-3074.
4. Albain K.S., Czerlanis C., Rajan P., Zlobin A., Godellas C., Bova D., Lo S.S., Robinson P., Sarker S., Gaynor E.R., Cooper R., Aranha G., Czaplicki K., Busby B., Rizzo P., Chisamore M., Demuth T., Blackman S., Watters J., Stiff P., Fuqua S.A.W., Miele L. Combination of notch inhibitor MK-0752 and endocrine therapy for early stage ERα+breast cancer in a presurgical window pilot study. Cancer Res. 2010, 70(24):PD05-PD12.
5. Alao J.P., Lam E.W., Ali S., Buluwela L., Bordogna W., Lockey P., Varshochi R., Stavropoulou A.V., Coombes R.C., Vigushin D.M. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin. Cancer Res. 2004, 10:8094-8104.
6. Anderson G.L., Chlebowski R.T., Aragaki A.K., Kuller L.H., Manson J.E., Gass M., Bluhm E., Connelly S., Hubbell F.A., Lane D., Martin L., Ockene J., Rohan T., Schenken R., Wactawski-Wende J. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012, 13:476-486.
7. André F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M., Hurvitz S.A., Turner N., Rugo H., Smith J.W., Deudon S., Shi M., Zhang Y., Kay A., Graus Porta D., Yovine A., Baselga J. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 2013, 19:3693-3702.
8. Ariazi E.A., Cunliffe H.E., Lewis-Wambi J.S., Slifker M.J., Willis A.L., Ramos P., Tapia C., Kim H.R., Yerrum S., Sharma C.G., Nicolas E., Balagurunathan Y., Ross E.A., Jordan V.C. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc. Natl. Acad. Sci. USA 2011, 108:18879-18886.
9. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, 2008. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53.
10. Arpino G., Gutierrez C., Weiss H., Rimawi M., Massarweh S., Bharwani L., De Placido S., Osborne C.K., Schiff R. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J. Natl. Cancer Inst. 2007, 99:694-705.
11. Atzori F., Tabernero J., Cervantes A., Prudkin L., Andreu J., Rodríguez-Braun E., Domingo A., Guijarro J., Gamez C., Rodon J., Di Cosimo S., Brown H., Clark J., Hardwick J.S., Beckman R.A., Hanley W.D., Hsu K., Calvo E., Roselló S., Langdon R.B., Baselga J. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17:6304-6312.
12. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., Abadie-Lacourtoisie S., Eymard J.C., Debled M., Spaëth D., Legouffe E., Allouache D., El Kouri C., Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 2012, 30:2718-2724.
13. Bachman K.E., Argani P., Samuels Y., Silliman N., Ptak J., Szabo S., Konishi H., Karakas B., Blair B.G., Lin C., Peters B.A., Velculescu V.E., Park B.H. The PIL3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3:772-775.
14. Bardon S., Vignon F., Chalbos D., Rochefort H. RU 486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J. Clin. Endocrinol. Metab. 1985, 50:692-697.
15. Barrie S.E., Potter G.A., Goddard P.M., Haynes B.P., Dowsett M., Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 1994, 50:267-273.
16. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., Beck J.T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366:520-529.
17. Baselga J., Roche H., Fumoleau P., Campone M., Colomer R., Cortes-Funes H., Gil M., Chan S., Boni J., Kong S., Cincotta M., Moore L. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study. Breast Cancer Res. Treat. 2005, 94(Suppl 1). (abstract 1068).
18. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., Campone M., Kubista E., Greil R., Bianchi G., Steinseifer J., Molloy B., Tokaji E., Gardner H., Phillips P., Stumm M., Lane H.A., Dixon J.M., Jonat W., Rugo H.S. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 2009, 27:2630-2637.
19. Basu B., Ang J.E., Crawley D., Folkerd E., Sarker D., Blanco-Codesido Moran M.K., Wan S., Dobbs N., Raynaud F., Johnston S.R.D., Dowsett M., Tutt A.N.J., Spicer J.F., Swanton C., De Bono J.S. Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor - (ER) or androgen receptor (AR) - positive advanced breast carcinoma resistant to standard endocrine therapies. J. Clin. Oncol. 2011, 29. (abstract 2525).
20. Beatson C.T. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:104-107.
21. Bertelli G., Garrone O., Merlano M., Occelli M., Bertolotti L., Castiglione F., Pepi F., Fusco O., Del Mastro L., Leonard R.C. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005, 69:471-477.
22. Bergh J., Jönsson P.E., Lidbrink E.K., Trudeau M., Eiermann W., Brattström D., Lindemann J.P., Wiklund F., Henriksson R. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J. Clin. Oncol. 2012, 30:1919-1925.
23. Berstein L.M., Yue W., Wang J.P., Santen R.J. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res. Treat. 2011, 128:109-117.
24. Bhattacharyya, G.S., Biswas, J., Singh, J.K., Singh, M., Govindbabu, K., Ranade, A.A., Malhotra, H., Parikh, P.M., Shahid, T., Basu, S., 2011. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. In: European Multidiscliplinary Cancer Congress, Edition Stockholm, Sweden.
25. Mouridsen H., Giobbie-Hurder A., Goldhirsch A., Thurlimann B., Paridaens R., Smith I., Mauriac L., Forbes J.F., Price K.N., Regan M.M., Gelber R.D., Coates A.S. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl. J. Med. 2009, 361:766-776. BIG 1-98 Collaborative Group.
26. Billich A., Nussbaumer P., Lehr P. Stimulation of MCF-7 breast cancer cell proliferation by estrone sulphate and dehydroepiandrosterone sulfate: inhibition by novel non-steroidal sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 2000, 73:225-235.
27. Bliss J.M., Kilburn L.S., Coleman R.E., Forbes J.F., Coates A.S., Jones S.E., Jassem J., Delozier T., Andersen J., Paridaens R., van de Velde C.J., Lønning P.E., Morden J., Reise J., Cisar L., Menschik T., Coombes R.C. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J. Clin. Oncol. 2012, 30:709-717.
28. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., Paladini G., Mesiti M., Romeo D., Rinaldini M., Scali S., Porpiglia M., Benedetto C., Restuccia N., Buzzi F., Franchi R., Massidda B., Distante V., Amadori D., Sismondi P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J. Clin. Oncol. 2005, 23:5138-5147.
29. Bonanni B., Puntoni M., Cazzaniga M., Pruneri G., Serrano D., Guerrieri-Gonzaga A., Gennari A., Trabacca M.S., Galimberti V., Veronesi P., Johansson H., Aristarco V., Bassi F., Luini A., Lazzeroni M., Varricchio C., Viale G., Bruzzi P., Decensi A. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J. Clin. Oncol. 2012, 30:2593-2600.
30. Bonneterre J., Buzdar A., Nabholtz J.M., Robertson J.F., Thürlimann B., von Euler M., Sahmoud T., Webster A., Steinberg M., Arimidex Writing Committee, Investigators Committee Members Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92:2247-2258.
31. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., von Euler M. Anastrozole versis tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J. Clin. Oncol. 2000, 18(22):3748-3757.
32. Boulay A., Rudloff J., Ye J., Zumstein-Mecker S., O'Reilly T., Evans D.B., Chen S., Lane H.A. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005, 11:5319-5328.
33. Boyd S. Remarks on oophorectomy in the treatment of cancer of the breast. BMJ 1899, 1:257-262.
34. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
35. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Castigilone-Gertsch M., Gelber R.D., Rabaglio M., Smith I., Wardley A., Price K.N., Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl. J. Med. 2005, 353:2747-2757. Breast International Group (BIG) 1-98 Collaborative Group.
36. Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat. Rev. Cancer 2013, 13:385-396.
37. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., Giordano S.H., Hudis C.A., Malin J., Mamounas E.P., Rowden D., Solky A.J., Sowers M.R., Stearns V., Winer E.P., Somerfield M.R., Griggs J.J. American Society of Clinical Oncology clinical practice guidelines: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 2010, 28:3784-3796.
38. Burtrum D., Zhu Z., Lu D., Anderson D.M., Prewett M., Pereira D.S., Bassi R., Abdullah R., Hooper A.T., Koo H., Jimenez X., Johnson D., Apblett R., Kussie P., Bohlen P., Witte L., Hicklin D.J., Ludwig D.L. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003, 63:8912-8921.
39. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001, 276:9817-9824.
40. Carboni J.M., Wittman M., Yang Z., Lee F., Greer A., Hurlburt W., Hillerman S., Cao C., Cantor G.H., Dell-John J., Chen C., Discenza L., Menard K., Li A., Trainor G., Vyas D., Kramer R., Attar R.M., Gottardis M.M. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 2009, 8:3341-3349.
41. Carlini P., Michelotti A., Ferretti G., Ricci S., Giannarelli D., Pellegrini M., Cresti N., Di Cosimo S., Bria E., Papaldo P., Fabi A., Ruggeri E.M., Milella M., Alimonti A., Salesi N., Cognetti F. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest. 2007, 25:102-105.
42. Carlson R.W., Theriault R., Schurman C.M., Rivera E., Chung C.T., Phan S.-C., Arun B., Dice K., Chiv V.Y., Green M., Vicente Valero V. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J. Clin. Oncol. 2010, 28:3917-3921.
43. Carpenter R., Doughty J., Cordiner C., Moss N., Gandhi A., Wilson C., Andrews C., Gui G. A multi-center study to determine the optimum duration of neoadjuvant letrozole on tumour regression to permit breast conserving surgery - an interim analysis. Cancer Res. 2009, 69(24 Suppl). (abstract 1082).
44. Cash R., Brough A.J., Cohen M.N., Satoh P.S. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J. Clin. Endocrinol. Metab. 1967, 27:1239-1248.
45. Cataliotti L., Buzdar A.U., Noguchi S., Bines J., Takatsuka Y., Petrakova K., Dube P., de Oliveira C.T. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cáncer: the Pro-operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006, 106:2095-2103.
46. Celio L., Martinetti A., Ferrari L., Buzzoni R., Mariani L., Miceli R., Seregni E., Procopio G., Cassata A., Bombardieri E., Bajetta E. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. 1999, 19:2261-2268.
47. Chabbert-Buffet N., Meduri G., Bouchard P., Spitz I.M. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update 2005, 11:293-307.
48. Chabbert-Buffet N., Pintiaux A., Bouchard P. The imminent dawn of SPRMs in obstetrics and gynecology. Mol. Cell Endocrinol. 2012, 358:232-243.
49. Chakraborty A.K., Welsh A., Digiovanna M.P. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res. Treat. 2010, 120:327-335.
50. Chanplakorn N., Chanplakorn P., Suzuki T., Ono K., Chan M.S., Miki Y., Saji S., Ueno T., Toi M., Sasano H. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res. Treat. 2010, 120:639-648.
51. Cheung K.L., Agrawal A., Folkerd E., Dowsett M., Robertson J.F.R., Winterbottom L. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. EJC 2010, 46:2936-2942.
52. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., Fein L., Romieu G., Buzdar A., Robertson J.F., Brufsky A., Possinger K., Rennie P., Sapunar F., Lowe E., Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J. Clin. Oncol. 2008, 26:1664-1670.
53. Chin Y.S., Beresford M.J., Ravichandran D., Makris A. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast 2007, 16:436-439.
54. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1:707-717.
55. Clarke R.B., Laidlaw I.J., Jones L.J., Howell A., Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br. J. Cancer 1993, 67:606-611.
56. Coates A.S., Keshaviah A., Thürlimann B., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Colleoni M., Láng I., Del Mastro L., Smith I., Chirgwin J., Nogaret J.M., Pienkowski T., Wardley A., Jakobsen E.H., Price K.N., Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 2007, 25:486-492.
57. Coffer P.J., Jin J., Woodgett J.R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 1998, 335:1-13.
58. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474. Br. J. Cancer 1971, 25:270-275.
59. Colleoni M., Viale G., Zahrieh D., Pruneri G., Gentilini O., Veronesi P., Gelber R.D., Curigliano G., Torrisi R., Luini A., Intra M., Galimberti V., Renne G., Nolè F., Peruzzotti G., Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 2004, 10:6622-6628.
60. Colleoni M., Giobbie-Hurder A., Regan M.M., Thürlimann B., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Láng I., Smith I., Chirgwin J., Pienkowski T., Wardley A., Price K.N., Gelber R.D., Coates A.S., Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J. Clin. Oncol. 2011, 29:1117-1124.
61. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., Jassem J., Van de Velde C.J., Delozier T., Alvarez I., Del Mastro L., Ortmann O., Diedrich K., Coates A.S., Bajetta E., Holmberg S.B., Dodwell D., Mickiewicz E., Andersen J., Lønning P.E., Cocconi G., Forbes J., Castiglione M., Stuart N., Stewart A., Fallowfield L.J., Bertelli G., Hall E., Bogle R.G., Carpentieri M., Colajori E., Subar M., Ireland E., Bliss J.M., Intergroup Exemestane Study Survival and safety of exemestane versus tamoxifen after 2-3years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet 2007, 369:559-570.
62. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lønning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., Bliss J.M., van de Velde C., Intergroup Exemestane Study A randomized trial of exemestane after 2-3years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl. J. Med. 2004, 350:1081-1092.
63. Coombes R.C., Schmid P., Isambert N., Soulie P., Cardoso F., Besse-Hammer T., Lesimple T., Slosman D., Kornowski A., Fohanno V., Fumoleau P. A phase 1 dose escalation study of steroid sulfatase inhibitor BN83495/STX64 in postmenopausal women with ER positive breast cancer. Cancer Res. 2009, 69. abstract 4097.
64. Coombes, R.C., Cardoso, F., Isambert, N., Lesimple, T., Soulié, P., Peraire, C., Fohanno, V., Kornowski, A., Ali, T., Schmid, P., June 25, 2013. A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res. Treat. [Epub ahead of print].
65. Coombes R.C., Goss P., Dowsett M., Gazet J.C., Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984, 2:1237-1239.
66. Cristofanilli M., Valero V., Mangalik A., Royce M., Rabinowitz I., Arena F.P., Kroener J.F., Curcio E., Watkins C., Bacus S., Cora E.M., Anderson E., Magill P.J. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin. Cancer Res. 2010, 16:1904-1914.
67. Curley, M., Sabnis, G., Wille, L., Garcia, G., Moyo, V., Kazi, A., MacBeath, G., Brodie, A., 2013. MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model AACR annual meeting. (abstract 1072).
68. Danila D.C., Morris M.J., de Bono J.S., Ryan C.J., Denmeade S.R., Smith M.R., Tapln M.E., Bubley G.J., Kheoh T., Haqq C., Molina A., Anand A., Koscuiszka M., Larson S.M., Schwartz L.H., Fieisher M., Scher H.I. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28:1496-1501.
69. Dauvois S., Labrie F. Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors-role of aromatase. Breast Cancer Res. Treat. 1989, 13:61-69.
70. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106:1377-1388.
71. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. USA 1992, 89:4037-4041.
72. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., Abraham M., Alencar V.H., Badran A., Bonfill X., Bradbury J., Clarke M., Collins R., Davis S.R., Delmestri A., Forbes J.F., Haddad P., Hou M.F., Inbar M., Khaled H., Kielanowska J., Kwan W.H., Mathew B.S., Müller B., Nicolucci A., Peralta O., Pernas F., Petruzelka L., Pienkowski T., Rajan B., Rubach M.T., Tort S., Urrútia G., Valentini M., Wang Y., Peto R., for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group Long-term effects of continuing adjuvant tamoxifen to 10years versus stopping at 5years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012, 318:805-816.
73. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B.Jr, Saad F., Staffurth J.N., Mainwaring P., Harland S., Flaig T.W., Hutson T.E., Cheng T., Patterson H., Hainsworth J.D., Ryan C.J., Sternberg C.N., Ellard S.L., Fléchon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C.M., Scher H.I., COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer. N Engl. J. Med. 2011, 364:1995-2005.
74. Demers L.M., Lipton A., Harvey H.A., Kambic K.B., Grossberg H., Brady C., Santen R.J. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced breast cancer. J. Steroid Biochem. Mol. Biol. 1993, 44:687-691.
75. Del Giudice M.E., Fantus I.G., Ezzat S., McKeown-Eyssen G., Page D., Goodwin P.J. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res. Treat. 1998, 47:111-120.
76. Dickson C., Fantl V., Gillett C., Brookes S., Bartek J., Smith R., Fisher C., Barnes D., Peters G. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 1995, 90:43-50.
77. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., Verhoeven D., Pedrini J.L., Smirnova I., Lichinitser M.R., Pendergrass K., Garnett S., Lindemann J.P., Sapunar F., Martin M. Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 2010, 28:4594-4600.
78. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., Verhoeven D., Pedrini J.L., Smirnova I., Lichinitser M.R., Pendergrass K., Garnett S., Lindemann J.P., Sapunar F., Martin M. Erratum in: J. Clin. Oncol. 2011, 29:2293.
79. Doane A.S., Danso M., Lal P., Donaton M., Zhang L., Hudis C., Gerald W.L. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008.
80. Donnez J., Tatarchuk T.F., Bouchard P., Puscasiu L., Zakharenko N.F., Ivanova T., Ugocsai G., Mara M., Jilla M.P., Bestel E., Terrill P., Osterloh I., Loumaye E., PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl. J. Med. 2012, 366:409-420.
81. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., A'Hern R., Salter J., Detre S., Hills M., Walsh G., IMPACT Trialists Group Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl. Cancer Inst. 2007, 99:167-170.
82. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., Griffith C., Boeddinghaus I., Salter J., Detre S., Hills M., Ashley S., Francis S., Walsh G., IMPACT Trialists Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin. Cancer Res. 2005, 11:951s-958s.
83. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., Cuzick J., Houghton J., Wiliams N., Mallon E., Bishop H., Ellis I., Larismont D., Sasano H., Carder P., Cussac A.L., Knox F., Speirs V., Forbes J., Buzdar A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol. 2008, 26:1059-1065.
84. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., Buyse M., Baum M., Buzdar A., Colleoni M., Coombes C., Snowdon C., Gnant M., Jakesz R., Kaufmann M., Boccardo F., Godwin J., Davies C., Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 2010, 28:509-518.
85. Drury S.C., Detre S., Leary A., Salter J., Reis-Filho J., Barbashina V., Marchio C., Lopez-Knowles E., Ghazoui Z., Habben K., Arbogast S., Johnston S., Dowsett M. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr. Relat. Cancer 2011, 18:565-577.
86. Dunn S.E., Ehrlich M., Sharp N.J.H., Reiss K., Solomon G., Hawkins R., Baserga R., Barrett J.C. A dominant negative mutant of the insulin - like growth factor - 1 receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998, 58:3353-3361.
87. Early Breast Cancer Trialists' Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl. J. Med. 1988, 319:1681-1692.
88. Early Breast Cancer Trialists' Collaborative Group Relevance of breast cancer hormone receptors and other factors to the effi cacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
89. Ebbinghaus S., Blum J.L., Cortes J., Rugo H.S., Swanton C., Eaton L., Song Y., Zhang T., Baselga J. A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer. J. Clin. Oncol. 2011, 29. (abstract TPS110).
90. Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., Mauriac L., Ellis M., Lassus M., Chaudri-Ross H.A., Dugan M., Borgs M., Letrozole Neo-Adjuvant Breast Cancer Study Group Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann. Oncol. 2001, 12:1527-1532.
91. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe-Fehling E., Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001, 19:3808-3816.
92. Ellis M.J., Gao F., Dehdashti F., Jeffe D.B., Marcom P.K., Carey L.A., Dickler M.N., Silverman P., Fleming G.F., Kommareddy A., Jamalabadi-Majidi S., Crowder R., Siegel B.A. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009, 302:774-780.
93. Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., Parker J.S., Luo J., DeSchryver K., Allred D.C., Esserman L.J., Unzeitig G.W., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Watson M.A., Leitch M., Hunt K., Olson J.A. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2-3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J. Clin. Oncol. 2011, 29:2342-2349.
94. Ellis M.J., Tao Y., Luo J., A'Hern R., Evans D.B., Bhatnagar A.S., Chaudri Ross H.A., von Kameke A., Miller W.R., Smith I., Eiermann W., Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl. Cancer Inst. 2008, 100:1380-1388.
95. Ellis M.J., Coop A., Singh B., Tao Y., Llombart-Cussac A., Jänicke F., Mauriac L., Quebe-Fehling E., Chaudri-Ross H.A., Evans D.B., Miller W.R. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003, 63:6523-6531.
96. Engelman J.A., Jänne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 2005, 102:3788-3793.
97. Esteva F.J., Moulder S.L., Gonzalez-Angulo A.M., Ensor J., Murray J.L., Green M.C., Koenig K.B., Lee M.H., Hortobagyi G.N., Yeung S.C. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013, 2013(71):63-72.
98. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
99. Fagan D.H., Uselman R.R., Sachdev D., Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. 2012, 72:3372-3380.
100. Fan P., Wang J., Santen R.J., Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction withEGFR in MCF-7 breast cancer cells. Cancer Res. 2007, 67:1352-1360.
101. Fawell S.E., White R., Hoare S., Sydenham M., Page M., Parker M.G. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA 1990, 87:6883-6887.
102. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., Ginther C., Atefi M., Chen I., Fowst C., Los G., Slamon D.J. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11:R77.
103. Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., Ettl J., Patel R., Pinter T., Schmidt M., Shparyk Y., Thummala A.R., Voytko N.L., Breazna A., Kim S.T., Randolph S., Slamon D.J. Results of a randomized phase 2 study of PD 0332991, a cyclindependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER/HER2-advanced breast cancer (BC). Cancer Res. 2012, 72(suppl:24). (Asbtr No.S1-6).
104. Fiskus W., Ren Y., Mohapatra A., Bali P., Mandawat A., Rao R., Herger B., Yang Y., Atadja P., Wu J., Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin. Cancer Res. 2007, 13:4882-4890.
105. Foekens J.A., Peters H.A., Grebenchtchikov N., Look M.P., Meijer-van Gelder M.E., Geurts-Moespot A., van der Kwast T.H., Sweep C.G., Klijn J.G. High tumour levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001, 61:5407-5414.
106. Forward D.P., Cheung K.L., Jackson L., Robertson J.F. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br. J. Cancer 2004, 90:590-594.
107. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
108. Friedländer E., Barok M., Szöllosi J., Vereb G. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol. Lett. 2008, 116:126-140.
109. Gao J., Chesebrough J.W., Cartlidge S.A., Ricketts S.A., Incognito L., Veldman-Jones M., Blakey D.C., Tabrizi M., Jallal B., Trail P.A., Coats S., Bosslet K., Chang Y.S. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res. 2011, 71:1029-1040.
110. Gavine P.R., Mooney L., Kilgour E., Thomas A.P., Al-Kadhimi K., Beck S., Rooney C., Coleman T., Baker D., Mellor M.J., Brooks A.N., Klinowska T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012, 72:2045-2056.
111. Gee J.M., Harper M.E., Hutcheson I.R., Madden T.A., Barrow D., Knowlden J.M., McClelland R.A., Jordan N., Wakeling A.E., Nicholson R.I. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144:5105-5117.
112. Gennatas C., Michalaki V., Carvounis E., Psychogios J., Poulakaki N., Katsiamis G., Voros D., Kouloulias V., Mouratidou D., Tsavaris N. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006, 92:13-17.
113. Geisler J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole - of clinical importance?. Br J Cancer. 2011, 104:1059-1066.
114. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
115. Graham J.D., Mote P.A., Salagame U., van Dijk J.H., Balleine R.L., Huschtscha L.I., Reddel R.R., Clarke C.L. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 2009, 150:3318-3326.
116. Gucalp A., Tolaney S.M., Isakoff S.J., Ingle J.N., Liu M.C., Carey L.A., Blackwell K.L., Rugo H.S., Nabell L., Forero-Torres A., Stearns V., Momen L., Gonzalez J., Giri D.D., Patil S., Feigin K., Hudis C., Traina T.A. Targeting the androgen receptor (AR) in women with AR+ ER-/PR-metastatic breast cancer (MBC). J. Clin. Oncol. 2012, 30. (abstract 1006).
117. Gucalp A., Tolaney S.M., Isakoff S.J., Ingle J.N., Liu M.C., Carey L.A., Blackwell K.L., Rugo H.S., Nabell L., Forero-Torres A., Stearns V., Momen L., Gonzalez J., Akhtar A., Giri D.D., Patil S., Feigin K.N., Hudis C.A., Traina T.A. Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(-) metastatic breast cancer (MBC) (TBCRC011). Cancer Res. 2012, 72. (abstract P6-05-02).
118. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Pöstlberger S., Menzel C., Jakesz R., Seifert M., Hubalek M., Bjelic-Radisic V., Samonigg H., Tausch C., Eidtmann H., Steger G., Kwasny W., Dubsky P., Fridrik M., Fitzal F., Stierer M., Rücklinger E., Greil R., ABCSG-12 Trial Investigators Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl. J. Med. 2009, 360:679-691.
119. Goodman L.S., Wintrobe M.M., Dameshek W., Goodman M.J., Gilman A., McLennan M.T. Nitrogen mustard therapy: use of methyl-bis(beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 1946, 132:126-132.
120. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., Hartwick W., Hoffman B., Hood N. Fasting insulin and outcome in early stage breast cancer: Results of a prospective cohort study. J. Clin. Oncol. 2002, 20:42-51.
121. Goodwin P.J., Pritchard K.I., Ennis M., Clemons M., Graham M., Fantus I.G. Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 2008, 8:501-505.
122. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J., Pater J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 2005, 97:1262-1271.
123. Goss P.E., Ingle J.N., Pritchard K.I., Ellis M.J., Sledge G.W., Budd G.T., Rabaglio M., Ansari R.H., Johnson D.B., Tozer R., D'Souza D.P., Chalchal H., Spadafora S., Stearns V., Perez E.A., Liedke P.E., Lang I., Elliott C., Gelmon K.A., Chapman J.A., Shepherd L.E. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III Trial. J. Clin. Oncol. 2013, 31:1398-13404.
124. Gray, R.G., Rea, D., Handley, K., Bowden, S.J., Perry, P., Earl, H.M., Poole, C.J., Bates, T., Chetiyawardana, S., Dewar, J.A., Fernado, I.N., Grieve, R., Nichol, J., Rayter, Z., Robinson, A., Salman, A., Yarnold, J., Bathers, S., Marshall, A., Lee, M., on behalf of the aTTom collaborative group, 2013. Attom: Long term effects of continuing adjuvant tamoxifen to 10years versus stopping at 5years in 6953 women with early breast cancer. J. Clin. Oncol. 31. (abstract 5).
125. Grose R., Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005, 16:179-186.
126. Hadad S., Iwamoto T., Jordan L., Purdie C., Bray S., Baker L., Jellema G., Deharo S., Hardie D.G., Pusztai L., Moulder-Thompson S., Dewar J.A., Thompson A.M. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 2011, 128:783-794.
127. Haddow A., Watkinson J.M., Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ 1944, 393-398.
128. Haluska P., Dhar A., Hou X., Huang F., Nuyten D.S.A., Park J., Brodie A.H., Ingle J.N., Carboni J.M., Gottardis M.M., Wolff A.C., Finckenstein F.G. Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor resistant breast cancer. J. Clin. Oncol. 2011, 29. (abstract TPS111).
129. Haluska P., Shaw H.M., Batzel G.N., Yin D., Molina J.R., Molife L.R., Yap T.A., Roberts M.L., Sharma A., Gualberto A., Adjei A.A., de Bono J.S. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007, 13:5834-5840.
130. Harper-Wynne C.L., Sacks N.P., Shenton K., MacNeill F.A., Sauven P., Laidlaw I.J., Rayter Z., Miall S., Howes A., Salter J., Hills M.J., Lowe F.M., A'Hern R., Nasiri N., Doody D., Iqbal J., Dowsett M. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J. Clin. Oncol. 2002, 20:1026-1035.
131. Harrison H., Simões B.M., Rogerson L., Howell S.J., Landberg G., Clarke R.B. 2013 Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res. 2013, 15:R21.
132. Howell A., Cuzick J. Oestrogen and breast cancer: results from the WHI trial. Lancet Oncol. 2012, 13:437-438.
133. Howell S.J., Seif M.W., Armstrong A.C., Cope J., Wilson G., Welch R.S., Misra V., Ryder D., Blowers E., Palmieri C., Wardley A.M. A phase II trial of low dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to an aromatase inhibitor. Cancer Res. 2012, 72. (abstract P2-14-06).
134. Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20:3396-3403.
135. Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E., Watanabe T., Morris C., Webster A., Dimery I., Osborne C.K. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previoulsy untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. 2004, 22:1605-1613.
136. Hou X., Huang F., Macedo L.F., Harrington S.C., Reeves K.A., Greer A., Finckenstein F.G., Brodie A., Gottardis M.M., Carboni J.M., Haluska P. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011, 71:7597-7607.
137. Hodges-Gallagher L., Valentine C.D., Bader S.E., Kushner P.J. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res. Treat. 2007, 2007(105):297-309.
138. Horwitz K.B., Dye W.W., Harrell J.C., Kabos P., Sartorius C.A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc. Natl. Acad. Sci. 2008, 105:5774-5779.
139. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer 2007, 97:453-457.
140. Hudis C.A., Barlow W.E., Costantino J.P., Gray R.J., Pritchard K.I., Chapman J.-A.W., Sparano J.A., Hunsberger S., Enos R.A., Gelber R.D., Zujewski J.A. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. JCO 2007, 25:2127-2132.
141. Huober J., Fasching P.A., Barsoum M., Petruzelka L., Wallwiener D., Thomssen C., Reimer T., Paepke S., Azim H.A., Ragosch V., Kubista E., Baumgärtner A.K., Beckmann M.W., May C., Nimmrich I., Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012, 21:27-33.
142. Huggins C., Bergenstal D.M. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 1952, 12:134-141.
143. Iaffaioli R.V., Formato R., Tortoriello A., Del Prete S., Caraglia M., Pappagallo G., Pisano A., Gebbia V., Fanelli F., Ianniello G., Cigolari S., Pizza C., Marano O., Pezzella G., Pedicini T., Febbraro A., Incoronato P., Manzione L., Ferrari E., Marzano N., Quattrin S., Pisconti S., Nasti G., Giotta G., Colucci G., Southern Italy Oncology Group Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br. J. Cancer 2005, 92:1621-1625.
144. Jakesz R., Greil R., Gnant M., Schmid M., Kwasny W., Kubista E., Mlineritsch B., Tausch C., Stierer M., Hofbauer F., Renner K., Dadak C., Rücklinger E., Samonigg H., Austrian Breast, Colorectal Cancer Study Group Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J. Natl. Cancer Inst. 2007, 99:1845-1853.
145. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., Hilfrich J., Kwasny W., Menzel C., Samonigg H., Seifert M., Gademann G., Kaufmann M., Wolfgang J., on behalf of the ABCSG and the GABG Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. The Lancet 2005, 366:455-462.
146. Jelovac D., Macedo L., Goloubeva O.G., Handratta V., Brodie A.M. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005, 65:5439-5444.
147. Jeng M.H., Shupnik M.A., Bender T.P., Westin E.H., Bandyopadhyay D., Kumar R., Masamura S., Santen R.J. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998, 139:4164-4174.
148. Jiralerspong S., Palla S.L., Giordano S.H., Meric-Bernstam F., Liedtke C., Barnett C.M., Hsu L., Hung M.C., Hortobagyi G.N., Gonzalez-Angulo A.M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 2009, 27:3297-3302.
149. Jirstrom K., Stendahl M., Ryden L., Kronblad A., Bendahl P.O., Stal O., Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 2005, 65:8009-8016.
150. Johannessen D.C., Engan T., Di Salle E., Zurlo M.G., Paolini J., Ornati G., Piscitelli G., Kvinnsland S., Lonning P.E. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin. Cancer Res. 1997, 3:1101-1108.
151. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., Press M.F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27:5538-5546.
152. Johnston S.R., Kilburn L.S., Ellis P., Dodwell D., Cameron D., Hayward L., Im Y.H., Braybrooke J.P., Brunt A.M., Cheung K.L., Jyothirmayi R., Robinson A., Wardley A.M., Wheatley D., Howell A., Coombes G., Sergenson N., Sin H.J., Folkerd E., Dowsett M., Bliss J.M. SoFEA investigators, HYPERLINK "/pubmed/23902874"Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013, 14:989-998.
153. Johnston S.R.D., Basik M., Hegg R., Lausoontornsiri W., Grzeda L., Clemons M., Dreosti L.M., Ghiorghiu S., Mann H., Landers D., Stuart M., Cristofanilli M. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J. Clin. Oncol. 2013, 31. (abstract 531).
154. Jonat W., Gnant M., Boccardo F., Kaufmann M., Rubagotti A., Zuna I., Greenwood M., Jakesz R. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006, 7:991-996.
155. Jonat, W., Bachelot, T., Ruhstaller, T., Kuss, I., Reimann, U., Robertson, J.F.R., 2013. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann. Oncol. (advanced access on line).
156. Jones S.E., Seynaeve C., Hasenburg A., Rae D., Vannetzel J., Paridaens R., Markopoulos C., Hozumi Y., Putter H., Hille E., Kieback D., Asmar L., Smeets J., Urbanski R., Bartlett J.M., van de Velde C.J. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res. 2009, 69:67s. (abstract 15).
157. Kaleko M., Rutter W.G., Miller D.A. Overexpression of the human insulin - like growth factor - 1 receptor promotes ligand dependent neoplastic transformation. Mol. Cell Biol. 1990, 10:464-473.
158. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Révil C., Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 2009, 27:5529-5537.
159. Kaufmann M., Jonat W., Hilfrich J., Eidtmann H., Gademann G., Zuna I., von Minckwitz G. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J. Clin. Oncol. 2007, 25:2664-2670.
160. Kawai H., Li H., Avraham S., Jiang S., Avraham H.K. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int. J. Cancer 2003, 107:353-358.
161. Kennecke H.F., Olivotto I.A., Speers C., Norris B., Chia S.K., Bryce C., Gelmon K.A. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5years of tamoxifen. Ann. Oncol. 2007, 18:45-51.
162. Klijn J.G., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., Sylvester R., Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J. Clin. Oncol. 2001, 19:343-353.
163. Klijn J.G.M., de Jong F.H., Bakker G.H., Lamberts S.W.J., Rodenburg C.J., Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 1989, 49:2851-2856.
164. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., Barrow D., Wakeling A.E., Nicholson R.I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
165. Knowlden J.M., Hutcheson I.R., Barrow D., Gee J.M., Nicholson R.I. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005, 146:4609-4618.
166. Koper J.W., Molijn G.J., van Uffelen C.J., Stigter E., Lamberts S.W. Antiprogestins and iatrogenic glucocorticoid resistance. Life Sci. 1997, 60:617-624.
167. Krainick-Strobel U.E., Lichtenegger W., Wallwiener D., Tulusan A.H., Jänicke F., Bastert G., Kiesel L., Wackwitz B., Paepke S. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 2008, 8:62.
168. Larsson S.C., Mantzoros C.S., Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer 2007, 121:856-862.
169. LHRH-agonists in Early Breast Cancer Overview group, 2007. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet, 369, 1711-1723.
170. Leonhardt S.A., Edwards D.P. Mechanism of action of progesterone antagonists. Exp. Biol. Med. 2002, 227:969-980.
171. Lippman M., Bolan G., Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1976, 36:4595-4601.
172. Llombart A., Ravaioli A., Strauss L., Sy O., Abrahao F., Geese W.J., Lortholary A., Rea D., Ro J.-S., Sohn J., Kim S.-B., Curigliano R. Randomized phase II study of dasatinib vs placebo in addition to exemestane in advanced ER/PR-positive breast cance (BMS CA180-261 study). Cancer Res. 2011, 71. (abstract PD01-02).
173. Lønning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mickiewicz E., Celio L., Pitt P., Mita M., Aaronson N.K., Fowst C., Arkhipov A., Di Salle E., Polli A., Massimini G. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J. Clin. Oncol. 2000, 18:2234-2244.
174. Lonning P.E., Taylor P.D., Anker G., Iddon J., Wie L., Jorgensen L.M., Mella O., Howell A. High-dose estrogen treatment in post-menopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat. 2001, 67:111-116.
175. Lonning P.E. Lack of complete cross-resistance between difference aromatase inhibitors; a real finding in search for an explanation?. Eur. J. Cancer 2009, 45:527-535.
176. Luft R., Olivecrona H., Sjogren B. Hypofysektomi pa manniska. Nord. med. 1952, 47:351-354.
177. Macedo L.F., Sabnis G.J., Goloubeva O.G., Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008, 68:3516-3522.
178. Maggiolini M., Donzé O., Jeannin E., Andò S., Picard D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res. 1999, 59:4864-4869.
179. Mak B.C., Yeung R.S. The tuberous sclerosis complex genes in tumor development. Cancer Invest. 2004, 22:588-603.
180. Malini B., Purohit A., Ganeshapillai D., Woo L.W., Potter B.V., Reed M.J. Inhibition of steroid sulfatase activity by tricyclic coumarin sulphamates. J. Steroid Biochem. Mol. Biol. 2000, 75:253-258.
181. Mamounas E.P., Jeong J.H., Wickerham D.L., Smith R.E., Ganz P.A., Land S.R., Eisen A., Fehrenbacher L., Farrar W.B., Atkins J.N., Pajon E.R., Vogel V.G., Kroener J.F., Hutchins L.F., Robidoux A., Hoehn J.L., Ingle J.N., Geyer C.E., Costantino J.P., Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J. Clin. Oncol. 2008, 26:1965-1971.
182. Manders P., Beex L.V., Tjan-Heijnen V.C., Span P.N., Sweep C.G. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 2003, 98:2125-2132.
183. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
184. Martin M., Loibl S., von Minckwitz G., Morales S., Crespo C., Anton A., Guerrero A., Aktas B., Schoenegg W., Muñoz M., Garcia-Saenz J.A., Gil M., Ramos M., Carrasco E., Liedtke C., Wachsmann G., Mehta K., De la Haba J.R. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: first efficacy results from the LEA study. Cancer Res. 2012, 72. (abstract S1-7).
185. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 1995, 80:2918-2925.
186. Mayordomo, J., Llombart, A., Martin, M., Anton, A., Barnadas, A., Antolin, S., Ales-Martinez, J., Alvarez, I., 2006. Randomized multicenter crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) withadvanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. J. Clin. Oncol. 24, 37S.
187. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68:826-833.
188. Means-Powell J.A., Minton S.E., Mayer I.A, Abramson V.G., Ismail-Khan R., Arteaga C.L., Ayers D.A., Sanders M.S., Lush R.M., Miele L. A phase Ib dose escalation trial of RO4929097 (a - secretase inhibitor) in combination with exemestane in patients with ER+ metastatic breast cancer. Cancer Res. 2012, 72(24 Supplement). P2-14-04.
189. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., Lew D.L., Hayes D.F., Gralow J.R., Livingston R.B., Hortobagyi G.N. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl. J. Med. 2012, 367:435-444.
190. Miller T.W., Hennessy B.T., González-Angulo A.M., Fox E.M., Mills G.B., Chen H., Higham C., García-Echeverría C., Shyr Y., Arteaga C.L. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest. 2010, 120:2406-2413.
191. Miller T.W., Balko J.M., Fox E.M., Ghazoui Z., Dunbier A., Anderson H., Dowsett M., Jiang A., Smith R.A., Maira S.M., Manning H.C., González-Angulo A.M., Mills G.B., Higham C., Chanthaphaychith S., Kuba M.G., Miller W.R., Shyr Y., Arteaga C.l. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011, 1:338-351.
192. Milla-Santos A., Milla L., Portella J., Rallo L., Pons M., Rodes E., Casanovas J., Puig-Gali M. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am. J. Clin. Oncol. 2003, 26:317-322.
193. Morris K.T., Tohl-Fejel S.E., Schmidt J., Fletcher W.S., Pommier R.F. High dehydroepiandrosterone-sulphate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a new role for adrenalectomy. Surgery 2001, 130:947-953.
194. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Jaenicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Chaudri-Ross H., Lang R., Wyld P., Bhatnagar A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2003, 21:2101-2109.
195. Moy B., Lebrun F., Bellet M., Chow L., Lang I., Xu B., Badwe R.A., Hershman D.L., Leip E., Bardy-Bouxin N., Duvillie L., Neven P. Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC). J. Clin. Oncol. 2011, 29. (abstract 631).
196. Munster P.N., Thurn K.T., Thomas S., Raha P., Lacevic M., Miller A., Melisko M., Ismail-Khan R., Rugo H., Moasser M., Minton S.E. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 2011, 104:1828-1835.
197. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomized trial. Arimidex Study Group. 2000. J. Clin. Oncol. 2000, 18:3758-3767.
198. Niraula S., Dowling R.J.O., Ennis M., Chang M.C., Done S.J., Hood N., Escallon J., Leong W.L., McCready D.R., Reedijk M., Stambolic V., Goodwin P.J. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res. Treat. 2012, 135:821-830.
199. Nunn T.W. On Cancer of the Breast 1882, J&A Churchill, London, UK, pp. 71.
200. O'Hara J., Vareslija D., McBryan J., Bane F., Tibbitts P., Byrne C., Conroy R.M., Hao Y., Gaora P.O., Hill A.D., McIlroy M., Young L.S. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells. Clin. Cancer Res. 2012, 18:3305-3315.
201. Osborne C.K., Neven P., Dirix L.Y., Mackey J.R., Robert J., Underhill C., Schiff R., Gutierrez C., Migliaccio I., Anagnostou V.K., Rimm D.L., Magill P., Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin. Cancer Res. 2011, 17:1147-1159.
202. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., Webster A., Morris C., Elledge R., Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002, 20:3386-3395.
203. Ottaviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B., Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994, 54:2552-2555.
204. Pasanisi P., Berrino F., De Petris M., Venturelli E., Mastroianni A., Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int. J. Cancer 2006, 119:236-238.
205. Paridaens R.J., Dirix L.Y., Beex L.V., Nooij M., Cameron D.A., Cufer T., Piccart M.J., Bogaerts J., Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J. Clin. Oncol. 2008, 26:4883-4890.
206. Parisot J.P., Hu X.F., DeLuise M., Zalcberg J.R. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer 1999, 79:693-700.
207. Park I.H., Ro J., Lee K.S., Kim E.A., Kwon Y., Nam B.H., Jung S.Y., Lee S., Kim S.W., Kang H.S. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J. Clin. Oncol. 2010, 28:2705-2711.
208. Perrault D., Eisenhauer E.A., Pritchard K.I., Panasci L., Norris B., Vandenberg T., Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Goup study. J. Clin. Oncol. 1996, 14:2709-2712.
209. Phillips G.D., Li G., Dugger D.L., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280-9290.
210. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat, Rev. Cancer 2012, 12:159-169.
211. Polychronis A., Sinnett H.D., Hadjiminas D., Singhal H., Mansi J.L., Shivapatham D., Shousha S., Jiang J., Peston D., Barrett N., Vigushin D., Morrison K., Beresford E., Ali S., Slade M.J., Coombes R.C. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005, 6:383-391.
212. Potter G.A., Barrie S.E., Jarman M., Rowlands M.G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 1995, 38(13):2463-2471.
213. Porta C., Osanto S., Ravaud A., Climent M.A., Vaishampayan U., White D.A., Creel P., Dickow B., Fischer P., Gornell S.S., Meloni F., Motzer R.J. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 2011, 47:1287-1298.
214. Poulin R., Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res. 1986, 46:4933-4937.
215. Price K.N., Goldhirsch A. Clinical trial update: international Breast Cancer Study Group. Breast Cancer Res. 2005, 7:252-254.
216. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011, 16(Suppl 2):32-44.
217. Regan M.M., Pagani O., Walley B., Torrisi R., Perez E.A., Francis P., Fleming G.F., Price K.N., Thürlimann B., Maibach R., Castiglione-Gertsch M., Coates A.S., Goldhirsch A., Gelber R.D. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? SOFT/TEXT/PERCHE Steering Committee; International Breast Cancer Study Group. Ann Oncol. 2008, 19:1231-1241.
218. Regan M.M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., Forbes J.F., Smith I., Láng I., Wardley A., Rabaglio M., Price K.N., Gelber R.D., Coates A.S., Thürlimann B., BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1years median follow-up. Lancet Oncol. 2011, 12:1101-1108.
219. Rini B.L. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 2008, 1(14(5)):1286-1290.
220. Robertson J.F.R., Willsher P.C., Winterbottom L., Blamey R.W., Thorpe S. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur. J. Cancer 1999, 35:214-218.
221. Robertson J.F., Erikstein B., Osborne K.C., Pippen J., Come S.E., Parker L.M., Gertler S., Harrison M.P., Clarke D.A. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin. Pharmacokinet. 2004, 43:529-538.
222. Robertson J.F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E., Lindemann J., Ellis M.J. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J. Clin. Oncol. 2009, 27:4530-4535.
223. Robertson J.F., Ferrero J.M., Bourgeois H., Kennecke H., de Boer R.H., Jacot W., McGreivy J., Suzuki S., Zhu M., McCaffery I., Loh E., Gansert J.L., Kaufman P.A. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013, 14:228-235.
224. Romieu G., Maudelonde T., Ulmann A., Pujol H., Grenier J., Cavalie G., Khalaf S., Rochefort H. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull. Cancer 1987, 74:455-459.
225. Rudas M., Lehnert M., Huynh A., Jakesz R., Singer C., Lax S., Schippinger W., Dietze O., Greil R., Stiglbauer W., Kwasny W., Grill R., Stierer M., Gnant M.F., Filipits M. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin. Cancer Res. 2008, 14:1767-1774.
226. Ryan P.D., Neven P., Blackwell K.L., Dirix L.Y., Barrios C.H., Miller W.H., Fein L.E., Fenton D., Benner R.J., Meech S.J., Paccagnella L., Sleight B., Yee D., Goss P.E. Figitumumab plus exemestane versus exemestane as first-line treatment of postmenopausal hormone receptor-positive advanced breast cancer: a randomized, open-label phase II trial. Cancer Res. 2011, 71. (abstract P1-17-01).
227. Sabnis G.J., Kazi A., Goloubeva O., Brodie A.M.H. HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2. Cancer Res. 2010, 70. (abstract PD05-03).
228. Sabnis G.J., Goloubeva O., Chumsri S., Nguyen N., Sukumar S., Brodie A.M. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor, entinostat, sensitizes ER negative tumors to letrozole. Cancer Res. 2011, 71:1893-1903.
229. Sanchez-Fructuoso A.I. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin. Drug Metab. Toxicol. 2008, 4:807-819.
230. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 1996, 14:2738-2746.
231. Schinzinger, A. (1889). Ueber carcinoma mammae. In 18th congress of the German society for surgery (vol. 16, pp. 55-56). Beilage zum Centralblatt fur Chirurgie.
232. Schinzinger, A. (1889). Ueber carcinoma mammae. In 18th Kongress, Berlin, Hirschwald (p. 28). Verhandlungen der Deutschen Gesellschaft fur Chirurgie. (abstract).
233. Schoeberl B., Faber A.C., Li D., Liang M.C., Crosby K., Onsum M., Burenkova O., Pace E., Walton Z., Nie L., Fulgham A., Song Y., Nielsen U.B., Engelman J.A., Wong K.K. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010, 70:2485-2494.
234. Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Ziltsova E.K., Ivanov V.G., Bozhok A.A., Melnikova O.A., Paltuev R.M., Kletzel A., Berstein L.M. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110:244-254.
235. Sharma A., Crook T., Thompson A., Palmieri C. Why biopsying metastatic breast cancer should be routine. Nat. Rev. Clin. Oncol. 2010, 7:72-74.
236. Shin I., Miller T., Arteaga C.L. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin. Cancer Res. 2006, 12:1008s-1012s.
237. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 2004, 96:926-935.
238. Sikora M.J., Cordero K.E., Larios J.M., Johnson M.D., Lippman M.E., Rae J.M. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res. Treat. 2009, 115:289-296.
239. Sikora M.J., Strumba V., Lipmann M.E., Johnson M.D., Rae J.M. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Res. Treat. 2012, 134:1027-1039.
240. Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Blohmer J.U., Ashley S.E., Francis S., Boeddinghaus I., Walsh G., IMPACT Trialists Group Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 2005, 23:5108-5116.
241. Smith I.E., Walsh G., Skene A., Llombart A., Mayordomo J.I., Detre S., Salter J., Clark E., Magill P., Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007, 25:3816-3822.
242. Song R.X., Zhang Z., Mor G., Santen R.J. Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 2005, 10:667-678.
243. Stanway S.J., Purohit A., Woo L.W., Sufi S., Vigushin D., Ward R., Wilson R.H., Stanczyk F.Z., Dobbs N., Kulinskaya E., Elliott M., Potter B.V., Reed M.J., Coombes R.C. Phase I study of STX 64 (667 coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 2006, 12:1585-1592.
244. Steele N., Zekri J., Coleman R., Leonard R., Dunn K., Bowman A., Manifold I., Kunkler I., Purohit O., Cameron D. Exemestane in metastatic breast cancer: effective therapy after third generation non-steroidal aromatase inhibitor failure. Breast 2006, 15:430-436.
245. Stoll B.A. Progestin therapy of breast cancer - comparison of agents. Br. Med. J. 1967, 3:338-341.
246. Suzuki T., Nakata T., Miki Y., Kaneko C., Moriya T., Ishida T., Akinaga S., Hirakawa H., Kimura M., Sasano H. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 2003, 63:2762-2770.
247. Teng D.H., Hu R., Lin H., Davis T., IIiev D., Frye C., Swedlund B., Hansen K.L., Vinson V.L., Gumpper K.L., Ellis L., El-Naggar A., Frazier M., Jasser S., Langford L.A., Leed J., Mills G.B., Pershouse M.A., Pollack R.E., Tornos C., Troncoso P., Yung W.L., Fujii G., Berson A., Bookstein R., Bolen J.B., Tavtigian S.V., Steck P.A. MMAC1/PTEN mutations in primary tumour specimens and tumour cell lines. Cancer Res. 1997, 57:5221-5225.
248. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group, 2002. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139.
249. Thürlimann B., Robertson J.F., Nabholtz J.M., Buzdar A., Bonneterre J., Arimidex Study Group Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur. J. Cancer 2003, 39:2310-2317.
250. Tokunaga E., Kataoka A., Kimura Y., Oki E., Mashino K., Nishida K., Koga T., Morita M., Kakeji Y., Baba H., Ohno S., Maehara Y. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur. J. Cancer 2006, 42:629-635.
251. Tokunaga E., Kimura Y., Mashino K., Oki E., Kataoka A., Ohno S., Morita M., Kakeji Y., Baba H., Maehara Y. Activation of PI3K/Akt signaling and hormone resistance breast cancer. Breast Cancer 2006, 13:137-144.
252. Torrisi R., Bagnardi V., Pruneri G., Ghisini R., Bottiglieri L., Magni E., Veronesi P., D'Alessandro C., Luini A., Dellapasqua S., Viale G., Goldhirsch A., Colleoni M. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br. J. Cancer 2007, 97:802-808.
253. Traina T.A., Rugo H.S., Caravelli J.F., Patil S., Yeh B., Melisko M.E., Park J.W., Geneus S., Paulson M., Grothusen J., Seidman A.D., Fornier M., Lake D., Dang C., Robson M., Theodoulou M., Flombaum C.D., Norton L., Hudis C.A., Dickler M.N. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J. Clin. Oncol. 2010, 28:628-633.
254. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., Natrajan R., Marchio C., Iorns E., Mackay A., Gillett C., Grigoriadis A., Tutt A., Reis-Filho J.S., Ashworth A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010, 70:2085-2094.
255. Utsumi T., Yoshimura N., Takeuchi S., Ando J., Maruta M., Maeda K., Harada N. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 1999, 59:377-381.
256. Utsumi T., Yoshimura N., Takeuchi S., Maruta M., Maeda K., Harada N. Elevated steroid sulfatase expression in breast cancer. J. Steroid Biochem. Mol. Biol. 2000, 73:141-145.
257. Vallabhaneni S., Nair B.C., Cortez V., Challa R., Chakravarty D., Tekmal R.R., Vadlamudi R.K. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res. Treat. 2011, 130:377-385.
258. van de Velde C.J., Rea D., Seynaeve C., Putter H., Hasenburg A., Vannetzel J.M., Paridaens R., Markopoulos C., Hozumi Y., Hille E.T., Kieback D.G., Asmar L., Smeets J., Nortier J.W., Hadji P., Bartlett J.M., Jones S.E. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase three trial. The Lancet 2011, 377:321-331.
259. Viale G., Giobbie-Hurder A., Regan M.M., Coates A.S., Mastropasqua M.G., Dell'Orto P., Maiorano E., MacGrogan G., Braye S.G., Ohlschlegel C., Neven P., Orosz Z., Olszewski W.P., Knox F., Thürlimann B., Price K.N., Castiglione-Gertsch M., Gelber R.D., Gusterson B.A., Goldhirsch A., Breast International Group Trial 1-98 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrineresponsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J. Clin. Oncol. 2008, 26:5569-5575.
260. Viale G., Speirs V., Bartlett J.M., Mousa K., Kalaitzaki E., Palmieri C., Reed S., Bliss J., Coombes R.C. prognostic and predictive value of IHC4 and ER in the Intergroup Exemestane Study (IES). Ann. Oncol. 2013, 24(Suppl 3):iii37.
261. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kInase-AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
262. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
263. Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R., Balimane P., Chang C., Chen C., Discenza L., Frennesson D., Gottardis M.M., Greer A., Hurlburt W., Johnson W., Langley D.R., Li A., Li J., Liu P., Mastalerz H., Mathur A., Menard K., Patel K., Sack J., Sang X., Saulnier M., Smith D., Stefanski K., Trainor G., Velaparthi U., Zhang G., Zimmermann K., Vyas D.M. The discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J. Med. Chem. 2009, 52:7360-7363.
264. Wolff A.C., Lazar A.A., Bondarenko I., Garin A.M., Brincat S., Chow L., Sun Y., Neskovic-Konstantinovic Z., Guimaraes R.C., Fumoleau P., Chan A., Hachemi S., Strahs A., Cincotta M., Berkenblit A., Krygowski M., Kang L.L., Moore L., Hayes D.F. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2013, 31:195-202.
265. Wright G.L., Blum J., Krekow L.K., McIntyre K.J., Wilks S.T., Rabe A.C., Vukelja S.J., Andersen J.C., Wang Y., Asmar L., O'Shaughnessy J. Randomized phase II trial of fulvestrant with or without dasatinib in postmenopausal patients with hormone receptor-positive metastatic breast cancer previously treated with an aromatase inhibitor. Cancer Res. 2011, 70. (abstract. PD01-01).
266. Xian W., Schwertfeger K.L., Vargo-Gogola T., Rosen J.M. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J. Cell Biol. 2005, 171:663-673.
267. Yang X., Ferguson A.T., Nass S.J., Phillips D.L., Butash K.A., Wang S.M., Herman J.G., Davidson N.E. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000, 60:6890-6894.
268. Yang X., Phillips D.L., Ferguson A.T., Nelson W.G., Herman J.G., Davidson N.E. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001, 61:7025-7029.
269. Yao K., Lee E.S., Bentrem D.J., England G., Schafer J.I., O'Regan R.M., Jordan V.C. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 2000, 6:2028-2036.
270. Yardley D.A., Burris H.A., Clark B.L., Shipley D., Rubin M., Barton J., Arrowsmith E., Hainsworth J.D. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptorpositive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin. Breast Cancer 2011, 11:146-152.
271. Yardley D.A., Ismail-Khan R.R., Melichar B., Lichinitser M., Munster P.N., Klein P.M., Cruickshank S., Miller K.D., Lee M.J., Trepel J.B. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 2013, 31:2128-2135.
272. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4:470-480.
273. Zardavas D., Baselga J., Piccart M. Emerging targeted agents in metastatic breast cancer. Nat. Rev. Clin. Oncol. 2013, 10:191-210.
274. Zhang Y., Moerkens M., Ramaiahgari S., de Bont H., Price L., Meerman J., van de Water B. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 2011, 13:R52.
275. Zhuang Y., Miskimins W.K. Cell cycle arrest in Metformin treated breastcancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal. 2008, 3:18.